Friday, July 20, 2018 9:37:53 AM
You missed this part of the article:
"it should be emphasized that eltrombopag is not likely to be a strong competitor (to Pluristem), since there is a lot more that needs to be done to repair the damage done by radiation."
The author of the article, Zach Hartman is PhD (biochemistry and molecular biology) and a very decent and intelligent observer of the biotech scene. When you leave out relevant information from the article, you undermine your argument (among other things).
An additional note: I see Novartis' interest as a POSITIVE! It shows that the target indications (multiple) represent a huge value. Pluristem will be there first and with a better product! How can I know this WITHOUT charts? Easy, look at the available data (as opposed to black magic).
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM